IGF2BP2 and hepatocellular carcinoma: We treated shIGF2BP2‐transfected HepG2 cells with sorafenib or apatinib at their IC50 concentrations and found that IGF2BP2 knockdown enhanced the inhibitory effects of sorafenib and apatinib on HCC cells.